金河生物科技股份有限公司 资金监管协议的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚假记载、误导性陈述或者重 大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）于2025年12月26日披露了《关于变更持续督导保荐机构 及保荐代表人的公告》。因公司聘请平安证券股份有限公司（以下简称"平安证券"）担任公司2025年度 以简易程序向特定对象发行股票的保荐机构，原保荐机构东方证券股份有限公司（以下简称"东方证 券"）对公司2021年度非公开发行股票并上市尚未完成的持续督导工作由平安证券承接。鉴于公司保荐 机构已变更，为规范募集资金管理和使用，保护中小投资者的权益，根据《上市公司募集资金监管规 则》《深圳证券交易所上市公司自律监管指引第1号一一主板上市公司规范运作》等相关法律、法规和 规范性文件及公司《募集资金管理办法》的相关规定，近日，公司与中国民生银行股份有限公司呼和浩 特分行、平安证券共同签订《募集资金三方监管协议》；公司及控股子公司金河佑本生物制品有限公司 （以下简称"金河佑本"）与招商银行股份有限公司呼和浩特分行、平安证券共同签订《募集资金四方监 管协议》。具体情况如下 ...

Core Viewpoint - The Ministry of Agriculture and Rural Affairs has approved the joint application of Qingdao Weilan Biological Co., Ltd. and other units for "Potassium Penicillin V Soluble Powder" as a new veterinary drug of category five, indicating a significant step in addressing the urgent market demand for effective treatments for necrotic enteritis in chickens [1] Group 1: Product Development - The product is specifically designed for the treatment of necrotic enteritis in chickens, a condition that currently lacks effective treatment options [1] - A total investment of 2.8067 million yuan has been made in the research and development of this product [1] - The product is notable for being usable during the laying period, having a short withdrawal period, high safety, and convenient dosage form [1] Group 2: Market Implications - There is a pressing market demand for medications that can be used during the egg-laying period, highlighting the product's potential to fill a significant gap in the market [1] - The issuance of the new veterinary drug certificate reflects the company's innovative capabilities and is expected to contribute to new revenue growth [1] - The product still requires approval of the product registration number before it can be marketed [1]